20240041816. USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS simplified abstract (KERYX BIOPHARMACEUTICALS, INC.)

From WikiPatents
Jump to navigation Jump to search

USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS

Organization Name

KERYX BIOPHARMACEUTICALS, INC.

Inventor(s)

Enrique Poradosu of Brookline MA (US)

James F. Oliviero, Iii of New York NY (US)

Ron Bentsur of Tenafly NJ (US)

USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240041816 titled 'USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS

Simplified Explanation

Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve iron storage parameters, increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients are disclosed.

  • The patent application describes methods for using ferric citrate to regulate serum phosphorus levels, increase serum bicarbonate levels, and improve iron storage parameters.
  • The methods also aim to increase iron absorption, maintain iron stores, treat iron deficiency, and treat anemia in chronic kidney disease patients.
  • By using ferric citrate, the need for IV iron and ESAs may be reduced, providing a potential alternative treatment option for patients.
  • The patent application does not oversell the technology and provides factual information about the potential benefits of using ferric citrate in chronic kidney disease patients.

Potential Applications

  • Treatment of chronic kidney disease patients with elevated serum phosphorus levels.
  • Management of iron deficiency and anemia in chronic kidney disease patients.
  • Alternative treatment option to reduce the need for IV iron and ESAs.

Problems Solved

  • Regulation of serum phosphorus levels in chronic kidney disease patients.
  • Improvement of iron storage parameters and iron absorption.
  • Treatment of iron deficiency and anemia in chronic kidney disease patients.

Benefits

  • Reduction in the need for IV iron and ESAs, potentially reducing treatment costs and improving patient outcomes.
  • Improved management of serum phosphorus levels and iron deficiency in chronic kidney disease patients.
  • Potential to increase serum bicarbonate levels and hemoglobin concentration in patients.


Original Abstract Submitted

methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (tsat), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for iv iron and/or reduce the need for erythropoiesis-stimulating agents (esas) in chronic kidney disease patients, are disclosed.

Retrieved from "http://wikipatents.org/index.php?title=20240041816._USE_OF_FERRIC_CITRATE_IN_THE_TREATMENT_OF_CHRONIC_KIDNEY_DISEASE_PATIENTS_simplified_abstract_(KERYX_BIOPHARMACEUTICALS,_INC.)&oldid=32420"